Home Cart Sign in  
Chemical Structure| 1050500-29-2 Chemical Structure| 1050500-29-2

Structure of Allitinib tosylate
CAS No.: 1050500-29-2

Chemical Structure| 1050500-29-2

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Allitinib tosylate (AST-1306 (TsOH)) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50 values of 0.5 and 3 nM, respectively. Allitinib tosylate inhibits ErbB4 with an IC50 of 0.8 nM. It is a phenylaminoquinazoline compound with anticancer activity.

Synonyms: AST-1306 (TsOH); Allitinib; AST-1306 (tosylate)

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Allitinib tosylate

CAS No. :1050500-29-2
Formula : C31H26ClFN4O5S
M.W : 621.08
SMILES Code : C=CC(NC1=CC2=C(NC3=CC=C(OCC4=CC=CC(F)=C4)C(Cl)=C3)N=CN=C2C=C1)=O.O=S(C5=CC=C(C)C=C5)(O)=O
Synonyms :
AST-1306 (TsOH); Allitinib; AST-1306 (tosylate)
MDL No. :MFCD17215204

Safety of Allitinib tosylate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Allitinib tosylate

RTK
JAK-STAT

Isoform Comparison

Biological Activity

Target
  • EGFR/ErbB1

    EGFR (T790M/L858R), IC50:12 nM

    EGFR, IC50:0.5 nM

  • HER2/ErbB2

    ErbB2, IC50:3.0 nM

  • ErbB4

    ErbB4, IC50:0.8 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
HCC-827 0.31 ± 0.07 µM (IC50) 72 hours Evaluate cytotoxic effect, IC50 value was 0.31 µM PMC9317664
NCI-H1975 0.21 ± 0.09 µM (IC50) 72 hours Evaluate cytotoxic effect, IC50 value was 0.21 µM PMC9317664
H292 1.32 ± 0.94 µM (IC50) 72 hours Evaluate cytotoxic effect, IC50 value was 1.32 µM PMC9317664
A549 3.92 ± 1.03 µM (IC50) 72 hours Evaluate cytotoxic effect, IC50 value was 3.92 µM PMC9317664
PC9 0.29 ± 0.03 µM (IC50) 72 hours Evaluate cytotoxic effect, IC50 value was 0.29 µM PMC9317664
Caski 0.024 ± 0.023 µM 72 hours Evaluate the effect of Allitinib on Caski cell viability, showing an IC50 of 0.024 ± 0.023 µM. PMC5327645
C-33A 0.10 ± 0.12 µM 72 hours Evaluate the effect of Allitinib on C-33A cell viability, showing an IC50 of 0.10 ± 0.12 µM. PMC5327645
SiHa 2.31 ± 0.28 µM 72 hours Evaluate the effect of Allitinib on SiHa cell viability, showing an IC50 of 2.31 ± 0.28 µM. PMC5327645
HeLa 2.34 ± 0.41 µM 72 hours Evaluate the effect of Allitinib on HeLa cell viability, showing an IC50 of 2.34 ± 0.41 µM. PMC5327645

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Chick embryo CAM model Local administration 1.5 µM 4 consecutive days Evaluate the anti-tumor effect of Allitinib in the CAM model, showing significant reduction in tumor size and angiogenesis. PMC5327645

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.61mL

0.32mL

0.16mL

8.05mL

1.61mL

0.81mL

16.10mL

3.22mL

1.61mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories